PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 31, 20260 citationsOpen Access

Extracellular vesicles in ophthalmology: innovations in diagnosis, therapy, and drug delivery.

View Full Paper
FAFatemeh AziziyanMMMohammadreza MahdipourBHBehnaz Hadi

Key Points

  • This review aims to highlight the role of extracellular vesicles in the diagnosis and treatment of ocular diseases.
  • Overview of EV applications in ophthalmology
  • Review techniques for isolating EVs from ocular biofluids
  • Discuss bioengineering strategies for drug delivery
  • EVs serve as promising biomarkers for early detection of ocular diseases.
  • High biocompatibility and low immunogenicity make EVs suitable for targeted therapy.
  • Recent developments in EV diagnostics and therapeutics show potential for clinical translation.

Abstract

Most cells have the ability to secrete extracellular vesicles (EVs), which are nanoscale membrane-bound vesicles. EVs carry a diverse array of biomolecule, that play key roles in immunological modulation, intercellular communication, and the regulation of pathological and physiological processes. For EV-based diagnosis of ocular diseases, eye-derived biofluids serve as important sources. EVs found in these biofluids have emerged as promising biomarkers for the early detection of ocular diseases, as their molecular cargo can reflect the biology of their parent cells. Furthermore, due to their high biocompatibility and low immunogenicity, EVs have been explored as therapeutic agents and targeted drug delivery nanocarriers in various ocular diseases. In this review, we summarize the advancements in EV-based research focused on the detection and treatment of ocular diseases. We provide an overview of the origin of EV applications in ophthalmology, review techniques for isolating EVs from ocular biofluids, highlight EV bioengineering strategies for drug delivery, and present recent developments in EV-based diagnostics and therapeutics. Finally, we discuss ongoing clinical trials and conclude with an overview of the current challenges and future considerations for the clinical translation of EV-based approaches in ocular disease.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Aziziyan et al. (2026) studied this question.

synapsesocial.com/papers/6a1bd1745783ba022b6fd07ehttps://doi.org/10.48620/98079
Ask AI
Helpful
Bookmark
Share
View Full Paper